


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE AND QILU PHARMACEUTICAL ENTER INTO
DRUG DEVELOPMENT COLLABORATION VALUED AT OVER HKD931
MILLION
TO ACCELERATE NOVEL CARDIOMETABOLIC THERAPIES**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, InSilico Medicine and Qilu Pharmaceutical Group, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center (“**Qilu Pharmaceutical**”), have entered into a strategic partnership on innovative drug development (the “**Collaboration**”) and signed the relevant agreement (the “**Agreement**”).

Through the Collaboration, the two parties aim to leverage InSilico Medicine’s proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

Under the terms of the Agreement, InSilico Medicine will utilize its proprietary Pharma.AI platform to focus on the design and optimization of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization procedures. The total contract value of the Agreement exceeds HKD931 million, including development and commercialization milestone payments, as well as single-digit royalties based on net sales.

About InSilico Medicine

InSilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

About Qilu Pharmaceutical

Qilu Pharmaceutical is a pharmaceutical enterprise group dedicated to the well-being of families and humanity, driven by innovation, and guided by a global vision. The company operates 11 major production bases spanning 6.1 square kilometers and employs over 36,000 employees. In 2024, it was ranked third in the “China Pharmaceutical Industry Top 100.”

Upholding the core values of “Great Medicine for the Benefit of Mankind,” the group is dedicated to meeting the public’s needs for a healthy and better life by delivering high-quality, trustworthy medicines worldwide. To date, it has launched more than 320 products, including 79 that were first-to-market or exclusive in China. Its products are exported to over 100 countries and regions, benefiting approximately 1.5 billion patients annually.

Committed to “innovation from the heart” and aligned with the forefront of global science and technology, the group has established six integrated research and development platforms across China and the U.S., building a globally influential product pipeline. The pipeline includes nearly 300 branded generic drugs and over 20 biosimilars under development, with more than 80 innovative medicines currently in various stages of clinical trials.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, January 27, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.